5th CML-CAB

CML-CAB 2018 I

CMLCAB-Logo

5th CML-CAB: Warsaw, Poland, 7-8 May 2018

 

On 7-8 May 2018, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its 5th meeting to discuss issues of major concern to the CML community.

CML-CAB Members attending the 5th CML-CAB as patient experts:

  • Jan Geissler, Germany (Co-chair)
  • Giora Sharf, Israel (Co-chair)
  • Mercedes Arteaga, Argentina (representing Latin America)
  • Yair Bar David (representing Israel)
  • Felice Bombaci, Italy (Western Europe)
  • Cornelia Borowczak, Germany
  • Silvia Castillo de Armas, Guatemala (Latin America)
  • Jelena Cugurovic(representing Serbia)
  • Rita Christensen, Denmark (representing Western Europe)
  • Pat García-González (representing Latin America)
  • Bahija Gouimi, Morocco (representing Africa and Middle East)
  • Lisa Machado, Canada (representing North America)
  • Šarūnas Narbutas, Lithuania (Eastern Europe)
  • Rod Padua, Philippines (representing East Asia and Pacific)
  • Jana Pelouchova, Czech Republic
  • Zack Pemberton-Whitely, United Kingdom
  • Gail Sperling, USA (representing North America)
  • YC Yong (Malaysia)

Plus, the CML Advocates Network team Lidija Pecova and Celia Marín.

CML-CAB with Novartis, 7th May 2018, 13:00-17:00

The following topics were discussed during the CML-CAB:

  • ABL001 - Clinical Development Program Updates
  • Patient-Reported Outcomes 
  • Precision Medicine –Novartis strategy in CML
  • TFR/CML educational materials
  • Novartis access program 
  • Discussion and Next Steps 

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

 

CML-CAB with Pfizer, 8th May 2018, 08:00-12:00

The following topics were discussed during the CML-CAB:

  • Clinical and Medical Update
  • Use of Patient report outcomes and in Bosutinib’s clinical trial program
  • Patient and physician information on Bosutinib
  • Access to Bosutinib
  • Collaboration with Pfizer and challenges
  • Discussion and Next Steps 

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

 

CML-CAB with Incyte 8th May 2018, 13:00-15:00

The following topics were discussed during the CML-CAB:

  • Clinical update and R&D
  • Access to Ponatinib
  • The collaboration of Incyte with the CML patient community
  • Incyte’s CML Patient Support Program
  • Discussion and Next Steps 

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

 

 


 
   
 

EU e-Privacy Directive